Literature DB >> 10587513

Choosing anticancer drug targets in the postgenomic era.

W G Kaelin1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10587513      PMCID： PMC409873          DOI： 10.1172/JCI8888

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  20 in total

1.  Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.

Authors:  Y N Chen; S K Sharma; T M Ramsey; L Jiang; M S Martin; K Baker; P D Adams; K W Bair; W G Kaelin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 2.  The emerging p53 gene family.

Authors:  W G Kaelin
Journal:  J Natl Cancer Inst       Date:  1999-04-07       Impact factor: 13.506

Review 3.  DNA tumor virus transforming proteins and the cell cycle.

Authors:  E Moran
Journal:  Curr Opin Genet Dev       Date:  1993-02       Impact factor: 5.578

4.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

Authors:  T Miyashita; J C Reed
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

5.  Gene deletion: a new target for cancer chemotherapy.

Authors:  E Frei
Journal:  Lancet       Date:  1993-09-11       Impact factor: 79.321

6.  Creation of human tumour cells with defined genetic elements.

Authors:  W C Hahn; C M Counter; A S Lundberg; R L Beijersbergen; M W Brooks; R A Weinberg
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

7.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.

Authors:  J D Oliner; J A Pietenpol; S Thiagalingam; J Gyuris; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

8.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

Authors:  F S Leach; T Tokino; P Meltzer; M Burrell; J D Oliner; S Smith; D E Hill; D Sidransky; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

9.  Tumour suppression by the human von Hippel-Lindau gene product.

Authors:  O Iliopoulos; A Kibel; S Gray; W G Kaelin
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

10.  Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells.

Authors:  H J Huang; J K Yee; J Y Shew; P L Chen; R Bookstein; T Friedmann; E Y Lee; W H Lee
Journal:  Science       Date:  1988-12-16       Impact factor: 47.728
View more
  13 in total

1.  Common pitfalls in preclinical cancer target validation.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2017-05-19       Impact factor: 60.716

2.  Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs.

Authors:  M V Blagosklonny; R Robey; S Bates; T Fojo
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

3.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

Authors:  Sarah K Knutson; Tim J Wigle; Natalie M Warholic; Christopher J Sneeringer; Christina J Allain; Christine R Klaus; Joelle D Sacks; Alejandra Raimondi; Christina R Majer; Jeffrey Song; Margaret Porter Scott; Lei Jin; Jesse J Smith; Edward J Olhava; Richard Chesworth; Mikel P Moyer; Victoria M Richon; Robert A Copeland; Heike Keilhack; Roy M Pollock; Kevin W Kuntz
Journal:  Nat Chem Biol       Date:  2012-09-30       Impact factor: 15.040

4.  Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

Authors:  Richard D Kennedy; Clark C Chen; Patricia Stuckert; Elyse M Archila; Michelle A De la Vega; Lisa A Moreau; Akiko Shimamura; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2007-04-12       Impact factor: 14.808

5.  Inhibition of ATM kinase activity does not phenocopy ATM protein disruption: implications for the clinical utility of ATM kinase inhibitors.

Authors:  Serah Choi; Armin M Gamper; Jason S White; Christopher J Bakkenist
Journal:  Cell Cycle       Date:  2010-10-27       Impact factor: 4.534

6.  SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery.

Authors:  Jie Wang; Min Wu; Xuhui Huang; Li Wang; Sophia Zhang; Hui Liu; Jie Zheng
Journal:  Database (Oxford)       Date:  2022-05-13       Impact factor: 4.462

Review 7.  Synthetic lethality as an engine for cancer drug target discovery.

Authors:  Alan Huang; Levi A Garraway; Alan Ashworth; Barbara Weber
Journal:  Nat Rev Drug Discov       Date:  2019-11-11       Impact factor: 84.694

8.  Synthetic genetic targeting of genome instability in cancer.

Authors:  Babu V Sajesh; Brent J Guppy; Kirk J McManus
Journal:  Cancers (Basel)       Date:  2013-06-24       Impact factor: 6.639

9.  Synthetic lethality: a framework for the development of wiser cancer therapeutics.

Authors:  William G Kaelin
Journal:  Genome Med       Date:  2009-10-27       Impact factor: 11.117

10.  Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.

Authors:  Jasper E Neggers; Brenton R Paolella; Adhana Asfaw; Michael V Rothberg; Thomas A Skipper; Annan Yang; Radha L Kalekar; John M Krill-Burger; Neekesh V Dharia; Guillaume Kugener; Jérémie Kalfon; Chen Yuan; Nancy Dumont; Alfredo Gonzalez; Mai Abdusamad; Yvonne Y Li; Liam F Spurr; Westley W Wu; Adam D Durbin; Brian M Wolpin; Federica Piccioni; David E Root; Jesse S Boehm; Andrew D Cherniack; Aviad Tsherniak; Andrew L Hong; William C Hahn; Kimberly Stegmaier; Todd R Golub; Francisca Vazquez; Andrew J Aguirre
Journal:  Cell Rep       Date:  2020-12-15       Impact factor: 9.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.